Maria E Pasquale - Net Worth and Insider Trading
Maria E Pasquale Net Worth
The estimated net worth of Maria E Pasquale is at least $5 Million dollars as of 2023-03-28. Maria E Pasquale is the EVP & General Counsel of Incyte Corp and owns about 68,524 shares of Incyte Corp (INCY) stock worth over $5 Million. Details can be seen in Maria E Pasquale's Latest Holdings Summary section.
Transaction Summary of Maria E Pasquale
Maria E Pasquale Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Maria E Pasquale owns 1 companies in total, including Incyte Corp (INCY) .
Click here to see the complete history of Maria E Pasquale’s form 4 insider trades.
Insider Ownership Summary of Maria E Pasquale
|Ticker||Comapny||Transaction Date||Type of Owner|
|INCY||Incyte Corp||2018-04-09||EVP & General Counsel|
Maria E Pasquale Latest Holdings Summary
Maria E Pasquale currently owns a total of 1 stock. Maria E Pasquale owns 68,524 shares of Incyte Corp (INCY) as of January 30, 2023, with a value of $5 Million.
Latest Holdings of Maria E Pasquale
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
Holding Weightings of Maria E Pasquale
Maria E Pasquale Form 4 Trading Tracker
According to the SEC Form 4 filings, Maria E Pasquale has made a total of 8 transactions in Incyte Corp (INCY) over the past 5 years, including 0 buys and 8 sells. The most-recent trade in Incyte Corp is the sale of 60,024 shares on January 30, 2023, which brought Maria E Pasquale around $5 Million.
Insider Trading History of Maria E Pasquale
Maria E Pasquale Trading Performance
Maria E Pasquale Ownership Network
Ownership Network List of Maria E Pasquale
Ownership Network Relation of Maria E Pasquale
Maria E Pasquale Owned Company Details
What does Incyte Corp do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Who are the key executives at Incyte Corp?
Maria E Pasquale is the EVP & General Counsel of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & Head of Tech. Operations Michael James Morrissey , and EVP & General Manager & Europe Jonathan Elliott Dickinson .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Maria E Pasquale made 1 insider transaction in Incyte Corp (INCY) with a net sale of 60,024. Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 30,111 shares made by Vijay K Iyengar , and a net sale of 46,866 shares made by Barry P Flannelly .
In summary, during the past 3 months, insiders sold 97,842 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 97,842 shares. During the past 18 months, 209,240 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,163 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Maria E Pasquale Mailing Address
Above is the net worth, insider trading, and ownership report for Maria E Pasquale. You might contact Maria E Pasquale via mailing address: C/o Incyte Corporation, 1801 Augustine Cut-off, Wilmington De 19803.